Cargando…
Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial
We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe for acute fluid-attenuated inversion recovery-negative stroke with unknown time of onset. METHODS—: This was an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients met the standar...
Ejemplares similares
-
Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial
por: Koga, Masatoshi, et al.
Publicado: (2023) -
Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society
por: TOYODA, Kazunori, et al.
Publicado: (2019) -
Evaluating the Potential Pathology and Short-Term Outcomes of Cryptogenic Stroke Using the Etiological Classification System
por: Shimizu, Takahiro, et al.
Publicado: (2023) -
Different aspects of early and late development of atrial fibrillation during hospitalization in cryptogenic stroke
por: Doijiri, Ryosuke, et al.
Publicado: (2021) -
Atrial Septal Aneurysm may Cause In-Hospital Recurrence of Cryptogenic Stroke
por: Kuriki, Ayako, et al.
Publicado: (2021)